B of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Tazeen Ahmad maintains a Buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and raises the price target from $28 to $33.
June 08, 2023 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities analyst Tazeen Ahmad maintains a Buy rating on 4D Molecular Therapeutics and raises the price target from $28 to $33.
The news of B of A Securities maintaining a Buy rating and raising the price target for FDMT from $28 to $33 indicates a positive outlook for the stock. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100